MR-guided focused ultrasound for painful bone metastases: safety when combined with chemotherapy by Joshua Meyer et al.
ORAL PRESENTATION Open Access
MR-guided focused ultrasound for painful bone
metastases: safety when combined with
chemotherapy
Joshua Meyer1*, Raphael Pfeffer2, Sergey Kanaev3, Dmitri Iozeffi4, David Gianfelice5, Pejman Ghanouni6,
Daniela Militianu7, Mark Hurwitz8
From Current and Future Applications of Focused Ultrasound 2014. 4th International Symposium
Washington, D.C, USA. 12-16 October 2014
Background/introduction
Magnetic Resonance guided Focused Ultrasound
(MRgFUS) is a non-invasive, non-ionizing treatment pro-
ducing thermal ablation using high intensity focused ultra-
sound and MR thermometry to denervate pain from bone
metastases. A recent phase III study comparing MRgFUS
to sham treatment for a painful bone metastasis allowed
patients to be treated with concurrent chemotherapy as
long as the regimen was stable for at least 4 weeks. We
performed a retrospective analysis of the safety of combi-
nation MRgFUS with active systemic chemotherapy in
patients treated on this study.
Methods
Chemotherapy data were available for 104 patients who
were treated with MRgFUS in 17 medical centers world-
wide as part of a randomized phase III study comparing
MRgFUS to sham treatment for a painful bone metastasis
previously irradiated or unsuitable for radiation therapy.
Patients were followed for 3 months. Response was
defined as a combination of at least two-point decrease
on a standard numerical rating scale and <25% increase
from baseline in analgesic medication at 3 months fol-
low-up. Toxicity data was collected as any adverse event
possibly related to treatment or its associated procedures.
In spite of being an expected part of the procedure, soni-
cation pain was scored as an event. Patients initially ran-
domized to sham treatment who were offered rescue
MRgFUS were also included in this analysis, bringing the
safety population to 121 patients. All comparisons were
performed using a z-score, with a significance level of
0.05.
Results and conclusions
Ninety patients were treated without chemotherapy, and
fourteen were treated with chemotherapy. There was no
significant difference between the response rates of the
chemotherapy group (71%) and the non-chemotherapy
group (68%) (p=0.78). The overall event rates were 57%
for chemotherapy patients and 45% for non-chemother-
apy patients (p=0.38). Sonication pain was not signifi-
cantly different between the groups, with 50% pain in
the chemotherapy group and 28% pain in the non-che-
motherapy group (p=0.11). Other events were limited to
one patient with numbness of the skin in the che-
motherapy group (7%). The non-chemotherapy group
reported 18 events that were not sonication pain (17%).
These rates were not significantly different (p=0.17). In
this retrospective analysis of a prospective study, no dif-
ference was found in efficacy or toxicity of MRgFUS
between patients receiving and not receiving active che-
motherapy. Further studies are necessary to confirm the
safety of these two modalities in combination. If con-
firmed, this may be an important reason to choose
MRgFUS in the palliation of pain from bone metastases.
Acknowledgements (Funding)
The authors wish to thank Insightec for help in collating the data.
Authors’ details
1Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States. 2Assuta
Hospital, Tel Aviv, Israel. 3N.N. Petrov Research Institute of Oncology, Saint
Petersburg, Russian Federation. 4Rostov Scientific Research Institute of
Oncology, Rostov-On-Don, Russian Federation. 5Laennec Imagix Imaging
Center • Medical Imaging, Ville Mont-Royal, Canada. 6Stanford University,
Stanford, California, United States. 7Rambam Health Care Campus, Haifa,
1Fox Chase Cancer Center, Philadelphia, Pennsylvania, United States
Full list of author information is available at the end of the article
Meyer et al. Journal of Therapeutic Ultrasound 2015, 3(Suppl 1):O50
http://www.jtultrasound.com/content/3/S1/O50
© 2015 Meyer et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://
creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Israel. 8Jefferson University Hospitals, Philadelphia, Pennsylvania, United
States.
Published: 30 June 2015
doi:10.1186/2050-5736-3-S1-O50
Cite this article as: Meyer et al.: MR-guided focused ultrasound for
painful bone metastases: safety when combined with chemotherapy.
Journal of Therapeutic Ultrasound 2015 3(Suppl 1):O50.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Meyer et al. Journal of Therapeutic Ultrasound 2015, 3(Suppl 1):O50
http://www.jtultrasound.com/content/3/S1/O50
Page 2 of 2
